Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from BioNTech SE

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

Benzinga

Why BioNTech Shares Are Surging Today

BioNTech SE (NASDAQ:BNTX) reported Q4 FY21 revenues of €5.53 billion compared to €345.4 million a year ago, mainly due to high demand for the company's COVID-19 vaccine. BioNTech and its partner Pfizer Inc (NYSE:PFE) delivered approximately 2.6 billion doses of Comirnaty/BNT162b2 worldwide in 2021, including over 1 billion doses to low- and middle-income countries. As…

Benzinga

FDA clears way for millions to get additional COVID-19 boosters

WASHINGTON — U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA clears way for millions to get additional COVID-19 boosters

U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

FDA clears way for millions to get additional COVID-19 boosters

Tribune News Service

3 Vaccine Stocks to Buy Following the Surge in COVID-19 Cases in China

China is battling with its worst COVID-19 outbreak since 2020. Surging cases of a new omicron variant worldwide are raising concerns that another COVID-19 wave is coming, which could drive demand for future vaccine orders. This bodes well for popular vaccine stocks Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX), and…

StockNews.com

Moderna requests FDA approval for fourth COVID shot for adults

Moderna Inc. has filed for U.S. regulatory clearance of a second COVID-19 booster shot for all adults, covering significantly more people than Pfizer Inc. and BioNTech SE’s request earlier this week for a more limited emergency authorization for those over 65.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Pfizer-BioNTech Seek FDA Approval For Second COVID-19 Booster In Elderly Population

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) filed an application with the

Benzinga

Here's Why BioNTech Shares Are Rising On Monday

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 14.8% at $155.65. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.

Benzinga

GeoVax Labs Retains CATO SMS To Manage Its Mid-Stage COVID-19 Vaccine Trials

GeoVax Labs Inc (NASDAQ:GOVX) has engaged CATO SMS to manage its two ongoing Phase 2 trials of its COVID-19 vaccine candidate, GEO-CM04S1. One is testing the safety and effectiveness of GEO-CM04S1 compared to the Pfizer Inc (NASDAQ:PFE) / BioNTech SE (NASDAQ:BNTX) in immunosuppressed patients with blood cancer. The other trial is testing GEO-CM04S1 as a booster in…

Benzinga

BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share…

Benzinga

Pfizer/BioNTech's COVID-19 Vaccine Mere 12% Effective In Kids 5-11 Years, New York Study Shows

According to a published study, Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) two-dose COVID-19 vaccine provided very little protection for children aged 5 to 11 years during the wave of o

Benzinga

Longer Waiting Period Between mRNA COVID-19 Doses May Cut Heart Inflammation Risk, CDC Suggests

The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc's (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna

Benzinga

BioNTech, Medigene Ink Immunotherapy Pact Against Cancer

BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Pfizer/BioNTech's Omicron-Targeted COVID-19 To Miss March Timeline: Reuters

Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process,

Benzinga

BioNTech Unveils First Modular mRNA Manufacturing Facility In Africa

BioNTech SE (NASDAQ: BNTX), which developed the first widely approved COVID-19 shot together with Pfizer Inc (NYSE: PFE),

Benzinga

Pfizer, Moderna COVID-19 Boosters Effectiveness Wanes After Four Months: CDC Study

COVID-19 vaccine boosters from Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ:

Benzinga

Why BioNTech Shares Are Falling Today

BioNTech SE (NASDAQ: BNTX) is trading lower Monday morning after the U.S. Food and Drug Administration (FDA) requested additional data before approving its COVID-19 vaccine for children aged six months to four years old.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

FDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest Children

Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) have

Tribune News Service

Pfizer seeking FDA clearance for COVID shot in children under 5

Pfizer Inc. and partner BioNTech SE have begun submitting data to U.S. regulators for authorization of their COVID-19 vaccine in children 6 months to 4 years old, according to people familiar with the matter, hastening an effort to get shots to younger kids after the omicron wave caused pediatric infections…

Benzinga

Pfizer Could Seek COVID-19 Vaccine Emergency Approval For Children Under 5 This Week

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are likely to submit a request for an emergency use authorization to the U.S.

Benzinga

Pfizer, BioNTech Launch Omicron-Targeted COVID-19 Vaccine Trial

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have

Asharq Al-Awsat

Pfizer and BioNTech Launch Trial of Omicron-Targeted COVID Vaccine

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the immune…

Benzinga

Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows

A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ:

StockNews.com

3 Biotech Stocks Poised to Outperform in 2022

With COVID-19 mutating into newer, more transmissible variants, biotechnology stocks have the potential to again outperform as authorities worldwide redouble their efforts at mass vaccinations. So, we think it could be wise to now add quality biotech stocks Vertex Pharmaceuticals (VRTX), BioNTech SE (BNTX), and Incyte (INCY) to one’s watchlist.…

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

US Food and Drug Administration

64 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.